Axoft Raises $60 Million to Read the Brains the Bedside Test Misses

Axoft has raised more than $60 million to commercialize a brain implant made of material it says is up to 10,000 times softer than the polyimide used in today's high-resolution neural probes. The company, spun out of Harvard research and based in Cambridge, Massachusetts, closed a $55 million Series A in April and is now pursuing its first U.S. regulatory approval for its implantable brain-computer interfaces.

The claim matters because of who Axoft is targeting first: patients in comas, vegetative states and minimally conscious states. CEO and co-founder Paul Le Floch argues the current standard of care cannot see them. "The current standard of care essentially amounts to a questionnaire that can miss signs of awareness," he told Pulse 2.0.

Why target disorders of consciousness?

The misdiagnosis numbers are stark. According to Le Floch, 43% of neuro-ICU patients are misdiagnosed on their state of consciousness. A recent New England Journal of Medicine study found 25% of patients without reflexes show signs of cognition on MRI — some level of awareness, with no way to respond.

The stakes are terminal. Over 70% of neuro-ICU deaths follow withdrawal of life-sustaining therapy, Le Floch said. "Patients and their families deserve better," he added. Axoft puts the market for addressing these misdiagnoses at $23 billion in the U.S. and UK alone, with global prevalence of 32 million to 160 million cases. Neurological disorders overall represent a $600 billion global burden, by the company's math.

What does the Fleuron material actually do?

Le Floch developed the material during his Harvard PhD in materials science and mechanical engineering, alongside co-founders Jia Liu, a Harvard bioengineering assistant professor now advising Axoft, and CTO Tianyang Ye. "Rigid materials always cause an immune response in the brain, shift position over time relative to the brain tissues, creating irreversible scarring and affecting the integrity of the data collected by the implant," he said. "We developed a new class of materials, named Fleuron, to solve this problem."

The company's spec sheet, as stated by Le Floch:

• 10,000 times softer than polyimide, the state-of-the-art implant material, and 1 million times softer than silicon
• Up to 32x more sensors per thread than current flexible probes
• Over 60% less signal transmission loss than polyimide
• Compatible with scalable semiconductor manufacturing, enabling small implants dense with sensors and stimulators

Le Floch describes Fleuron as "the chewing gum version of PTFE, or Teflon," with biocompatibility from its softness and chemical inertness. The softness, he says, lets the implant reach brain regions other high-resolution implants cannot, including deep structures, and record single-neuron signals over longer durations. An AI software layer decodes those signals into clinical insights for diagnosis and closed-loop therapies.

That is the pitch. Independent clinical validation so far consists of a small first-in-human study — four patients at The Panama Clinic last April, with implants tested during brain tumor surgeries in tissue already scheduled for removal.

How is the clinical program advancing?

Axoft is running a clinical research collaboration with Mass General Brigham, using Fleuron-based neural interfaces for cortical mapping, seizure onset mapping around tumors and language recognition tasks. Fast Company named the brain-computer interface to its "The Next Best Things in Tech" list, and the company won a MedTech Breakthrough Award. It is also a finalist for the Mid-State Grand Prize 2026 MedTech Innovator cohort — a group representing the top 4% of 1,835 global applicants.

Le Floch's stated next steps: expand clinical studies to 100 patients, begin in-house manufacturing at a new GMP facility in Cambridge, and pursue the first U.S. regulatory approval.

The material business is already generating revenue beyond implants. Axoft sells multiple versions of Fleuron for custom applications, and Le Floch sees uses in pacemakers, stents, organ-on-a-chip systems, microfluidics and biohybrid devices. "Our goal is for research and industry colleagues and patients to benefit from Fleuron by making it the new standard in biomedical engineering," he said.

Behind the near-term plans sit longer-term markets the company has not yet entered: generalized epilepsy and movement disorders. The takeaway: Axoft has the money and the material claims; the burden now is proving, at 100-patient scale, that softer implants translate into better diagnoses.